The American Society of Clinical Oncology (ASCO) has released a statement on use of the human papillomavirus vaccination (HPV) for cancer prevention. The statement aims to increase awareness of HPV–caused cancers, refocus the discussion of HPV vaccination on its ability to prevent cancer deaths, and increase HPV vaccination uptake via greater involvement of oncology professionals.

Among the recommendations:

• Increased education and awareness among health care professionals, policymakers, patients, and the public.

• Improved initiatives to ease access to vaccination services and limit out-of-pocket costs.

• Increased research to advance prevention of HPV-related cancers, with a focus on what is needed to improve how vaccination programs are implemented to enhance delivery and uptake.

The statement also urges oncologists to be aware of established HPV vaccine guidelines from the CDC and WHO regarding immune-compromised individuals, and safely recommend HPV vaccination along with other recommended vaccines for their patients when appropriate.

Citation: Bailey H, Chuang L, DuPont N, et al. American Society of Clinical Oncology Statement: Human papillomavirus vaccination for cancer prevention. J Clin Oncol. 2016; 34(15):1803-1812. doi:10.1200/JCO.2016.67.2014.